What is Epitope Diagnostics?
Epitope Diagnostics Inc. operates as a specialized medical device manufacturer with a core focus on the development and production of niche immunoassays. The company maintains a comprehensive product suite that includes ELISA kits, rapid testing platforms, and high-affinity antibodies. With ISO13485:2016 certification and US FDA registration, the organization provides essential diagnostic solutions to the global clinical and research communities. Their expertise spans critical medical domains, including oncology, infectious disease management, and the study of autoimmune disorders. By maintaining a focus on professional laboratory requirements, Epitope Diagnostics has established itself as a reliable partner in the healthcare technology ecosystem, delivering precision-engineered tools that facilitate accurate patient outcomes.
How much funding has Epitope Diagnostics raised?
Epitope Diagnostics has raised a total of $1.5M across 1 funding round:
Debt
$1.5M
Debt (2024): $1.5M with participation from Bank of America
Key Investors in Epitope Diagnostics
Bank of America
A global financial institution providing comprehensive banking and capital market services to support corporate growth and strategic debt financing.
What's next for Epitope Diagnostics?
With the recent procurement of $1.5M, Epitope Diagnostics is poised to transition into a more aggressive phase of market penetration and product diversification. The strategic allocation of these funds will likely prioritize the expansion of manufacturing capacity to meet the rising global demand for rapid, reliable diagnostic testing. Furthermore, the company is expected to leverage its strengthened balance sheet to deepen its research pipeline, potentially exploring new frontiers in molecular diagnostics and personalized medicine. As the firm navigates this enterprise-level growth stage, the focus will remain on maintaining its stringent quality management systems while scaling its commercial operations to serve a broader international client base.
See full Epitope Diagnostics company page
